THX Pharma Enters Strategic Licensing Agreement with Biocodex
THX Pharma has signed a strategic licensing agreement with the pharmaceutical group Biocodex for the development and commercial exploitation of two drug candidates. This agreement represents a total amount that could reach €173 million.
Details of the Agreement
The agreement between THX Pharma and Biocodex encompasses the global development and commercial exploitation of Batten-1, as well as TX01 in the United States and Canada. Batten-1 targets the juvenile form of Batten disease. TX01 is a new formulation intended for the treatment of Gaucher's disease and Niemann-Pick type C disease.
Additional Information
Broader Collaborations
TX01 is already subject to several licensing agreements with international pharmaceutical partners such as Exeltis and Biocodex for its development and commercialization in various regions of the world. THX Pharma is a biopharmaceutical company specialized in the development of innovative treatments for rare neurological diseases, listed on the Euronext Growth market in Paris.
